The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nonetheless, rodent models emphasise the importance of NLRP3 activation for inflammatory macrophage as well as fibrogenic stellate cell responses.64”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [64]
In the citing paper
“In NAFLD and NASH, the NLR family pyrin domain containing 3 (NLRP3) inflammasome has been identified as a central driver of inflammation – via activation of caspase 1 and the release of inflammatory cytokines (e.g., IL-1β) – and as an inducer of inflammatory (“pyroptotic”) cell death.64”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [64]
Citations
Cites
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death
Shi, J., Zhao, Y., Wang, K., Shi, X., Wang, Y., Huang, H., Zhuang, Y., Cai, T., Wang, F., & Shao, F. (2015) · Nature · doi:10.1038/nature15514 · Cited by 6,659
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling
Kayagaki, N., Stowe, I. B., Lee, B. L., O’Rourke, K., Anderson, K., Warming, S., Cuellar, T., Haley, B., Roose-Girma, M., Phung, Q. T., et al. (2015) · Nature · doi:10.1038/nature15541 · Cited by 3,686
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citation
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
“Inhibition of TLR4 or inflammasome activation demonstrated preclinical efficacy in mouse models but is currently not in late-stage development for the treatment of liver fibrosis 21,222 .”
Self-citationWen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
“The role of macrophage inflammasome activation in chronic liver diseases, such as ALD and NASH, has also been reported.(100) IL-1β, which is released as a result of inflammasome activation in KCs, plays a critical role in mediating alcohol-induced steatosis, inflammation, and liver injury.”
BackgroundSelf-citationMolecular Mechanisms That Link Oxidative Stress, Inflammation, and Fibrosis in the Liver
Ramos-Tovar, E., & Muriel, P. (2020) · Antioxidants · doi:10.3390/antiox9121279 · Cited by 340
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citation
Metadata
- Authors
- Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E.
- Affiliations
- Stiftung Charité (DE)
- University of California San Diego (US)
- Corresponding author
- Feldstein, Ariel E.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2020-06-11
- Volume
- 40
- Issue
- 03
- Pages
- 298-306
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W3035320104
- Semantic Scholar
- 037be5799886122d7579dfbba835734266590c6a
- Cited by
- 99
- References
- 77
- Citations by year
- 2026: 10 · 2025: 6 · 2024: 20 · 2023: 22 · 2022: 27 · 2021: 9 · 2020: 5
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH (R01 DK113592, U01 AA024206)
- German Research Foundation (WR173/3–1, SFB/TRR57)
- German Cancer Aid (70113000)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- NLRP3 inflammasome, nonalcoholic steatohepatitis, alcoholic hepatitis, hepatic steatosis, caspase-1, IL-1β, pyroptosis, liver inflammation, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, therapeutic target, prognostic factors
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Fatty Liver, Alcoholic, Female, Humans, Male, Disease Progression, Mice, Inflammasomes, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.1055/s-0040-1708540
- The paper
- Knorr, J., Wree, A., Tacke, F., & Feldstein, A. E. (2020). The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. Seminars in Liver Disease. https://doi.org/10.1055/s-0040-1708540
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.